Abstracts tagged "B cells"

Abstract Number: 2791 • 2018 ACR/ARHP Annual Meeting
Characterization of Monoclonal Anti-PAD4 Autoantibodies from Rheumatoid Arthritis Patients: Functional Implications for Citrullination and Disease Progression
Alejandro Gomez, Sarah Kongpachith, Nithya Lingampalli, Cecilia Cisar and William H. Robinson, Department of Medicine, Stanford University, Stanford, CA
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are present in two-thirds of patients with rheumatoid arthritis (RA), and target proteins that have been post-translationally modified by the…
Abstract Number: 19 • 2018 ACR/ARHP Annual Meeting
Citrulline-Multispecific B Cell Receptor Clades in Rheumatoid Arthritis
Philip J. Titcombe^1,2, Natalie Sippl³, Monika Hansson⁴, Lena Israelsson³, Khaled Amara³, Timothy B. Niewold⁵, Lars Klareskog², Vivianne Malmström² and Daniel L. Mueller⁶, ¹The Center for Immunology, Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ²Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Colton Center for Autoimmunity, New York University, New York, NY, ⁶Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) have proven highly useful as biomarkers in rheumatoid arthritis (RA) and appear to be important to disease pathogenesis. Nevertheless, the…
Abstract Number: 1082 • 2018 ACR/ARHP Annual Meeting
Peripheral Blood CD11c+ CD21- Age-Associated B Cells (ABCs) in Human Systemic Lupus Erythematosus Are Associated with Innate Type III Interferon and Disease Activity
Jennifer L. Barnas, Lin Gao, Mary O'Connell, Jennifer Albrecht, Nida Meednu, R. John Looney and Jennifer Anolik, Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by an interferon-stimulated gene (ISG) signature typically attributed to interferon (IFN)-α. However, ISGs can be induced by other…
Abstract Number: 2795 • 2018 ACR/ARHP Annual Meeting
IL-23 Acts through IL-23R+ Tfh cells to Promote Pathogenic IgG Autoantibody Formation in Lupus
Huixian Hong¹, Qi Wu², PingAr Yang², Bao Luo³, Jun Li⁴, Hao Li⁵, Daniel Cua⁶, Hui-Chen Hsu² and John D. Mountz⁷, ¹University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ³DIvision of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ⁵Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁶Discovery Research, Merck Research Laboratory, Palo Alto, CA, ⁷University of Alabama at Birmingham, Devision of Clinical Immunology and Rheumatology; University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: IL-23 is currently a target for several forms of autoimmune diseases, yet its role in promoting pathogenic autoantibody development is less clear. IL-23 was…
Abstract Number: 20 • 2018 ACR/ARHP Annual Meeting
Expression and Functions of the Transcription Factors Ikaros and Aiolos in Sjogren’s Syndrome and Systemic Lupus Erythematosus
Felice Rivellese^1,2, Daniele Mauro¹, Mattia Congia³, Elena Pontarini¹, Peter Schafer⁴, Michele Bombardieri^1,2, Costantino Pitzalis^1,5 and Myles J. Lewis^1,2, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kindgdom, London, United Kingdom, ²Barts Health NHS Trust & Barts and the London School of Medicine & Dentistry, London, United Kingdom, London, United Kingdom, ³Rheumatology and Rheumatology Unit, University Clinic and AOU of Cagliari, Cagliari, Italy, Cagliari, Italy, ⁴Celgene Corporation, Summit, NJ, ⁵Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
Background/Purpose: Polymorphisms of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), which are essential for the maturation, differentiation and survival of B cells, have been…
Abstract Number: 1083 • 2018 ACR/ARHP Annual Meeting
Changes of Innate Lymphoid Cells in Peripheral Blood of Patients with Systemic Lupus Erythematosus and Its Correlations with Clinical Markers
Hui Chu, Xiaomei Li, zhen Tan, ruolan Wu, Xiangpei Li, xuan Fang, xu Zhen and Guosheng Wang, The first affiliated hospital of university of Science and Technology of China, Hefei, China
Background/Purpose: Innate Lymphoid Cells (ILCs) are a novel group of innate immune cells, according to the cytokine profile, they were divided into three major subsets:…
Abstract Number: 2796 • 2018 ACR/ARHP Annual Meeting
Sex-Based Differences Control ABC Function in Swef-Deficient Mice
Michela Manni¹, Danny Flores-Castro², Chao Ye², Edd Ricker¹, Sanjay Gupta³, Yurii Chinenov⁴, Tania Pannellini² and Alessandra B. Pernis⁵, ¹Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Autoimmunity & Inflammation Research Program, Hospital for Special Surgery, New York, NY, ⁴Arthritis & Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, ⁵David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Age-associated B cells (ABCs) are a novel B cell subset, which expands with age in non-autoimmune mice but accumulates prematurely in autoimmune-prone strains. ABCs…
Abstract Number: 33 • 2017 ACR/ARHP Annual Meeting
B Cell Abnormalities in Patients with Chronic Cutaneous Lupus Erythematosus
Chungwen Wei¹, Aisha Hill², Kira Smith³, Ignacio Sanz¹, S. Sam Lim⁴ and Cristina Drenkard⁴, ¹Medicine, Emory University School of Medicine, Atlanta, GA, ²Medicine, Emory University School of Medicine, atlanta, GA, ³Emory University School of Medicine, Atlanta, GA, ⁴Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Lupus is a spectrum of disease with cutaneous lupus (CLE) without systemic features on one end and systemic lupus erythematosus (SLE) on the other.…
Abstract Number: 834 • 2017 ACR/ARHP Annual Meeting
Citrulline-Polyspecific B Cell Antigen Receptors Arising from Somatic Hypermutation within Clades Demonstrate Pathogenicity in Rheumatoid Arthritis
Philip J. Titcombe^1,2, Gustaf Wigerblad³, Natalie Sippl³, Na Zhang¹, Anna K. Shmagel⁴, Peter Sahlström⁵, Yue Jack Zhang¹, Laura Barsness Motschenbacher¹, Yogita Ghodke-Puranik⁶, Monika Hansson⁷, Lena Israelsson⁵, Timothy B. Niewold⁸, Lars Klareskog⁹, Camilla Svensson¹⁰, Khaled Amara⁷, Vivianne Malmström¹¹ and Daniel L. Mueller¹, ¹Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ²Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatic & Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ⁵Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁶Colton Center for Autoimmunity, New York University, New York, NY, ⁷Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁸Rheumatology and Immunology, Mayo Clinic, Rochester, MN, ⁹Rheumatology unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹⁰Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, ¹¹Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Citrulline–modified proteins arising from the post-translational modification of arginine residues are recognized as primary rheumatoid arthritis (RA) autoantigen targets based on the strong association…
Abstract Number: 2872 • 2017 ACR/ARHP Annual Meeting
Elevated mTORC1 Signature in B Cells from Sjögren’s Syndrome Patients: mTOR Inhibition As a Novel Therapeutic Strategy to Halt B Cell Hyperactivity
Sofie L.M. Blokland^1,2, Maarten R. Hillen^3,4, Rina G.K. Kommer-Wichers⁴, Aike A. Kruize², Timothy R.D.J. Radstake^2,5, Jasper C.A. Broen^2,4 and Joel A.G. van Roon^2,4, ¹Rheumatology & Clinical Immunology/ Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ⁵Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: A hallmark feature of primary Sjögren’s syndrome (pSS) is B cell hyperactivity, including presence of autoantibodies, aberrant presence of B cells and plasma cells…
Abstract Number: 34 • 2017 ACR/ARHP Annual Meeting
IL-23 Regulates Development of Spontaneous Germinal Centers and Pathogenic Autoantibody Production in BXD2 Mice
Huixian Hong¹, Qi Wu², PingAr Yang², Bao Luo³, Jun Li⁴, Hao Li⁵, Daniel Cua⁶, Hui-Chen Hsu² and John D. Mountz^2,7, ¹University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ³DIvision of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ⁵Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁶Discovery Research, Merck Research Laboratory, Palo Alto, CA, ⁷University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL
Background/Purpose: Targeting IL-23 to treat autoimmune disease and chronic inflammation is currently in development based on its pro-inflammatory function via regulating the activation of Th17…
Abstract Number: 835 • 2017 ACR/ARHP Annual Meeting
Generation of an Efficient CRISPR-Cas9 Editing Technique in Human Primary B Cells for the Targeted Study of Autoimmune Susceptibility Genes
Yuriy Baglaenko¹, Dario Ferri², Juan Carlos Zuniga-Pflucker³ and Joan E. Wither^2,4,5, ¹Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Immunology, University of Toronto, Toronto, ON, Canada, ³Biological Sciences, Sunnybrook Research Institute, Toronto, ON, Canada, ⁴Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁵Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Autoimmunity is a complex, poly-genic disorder that culminates in multi-organ damage. In systemic lupus erythematosus (SLE), the prototypic autoimmune disorder, a breakdown of tolerance…
Abstract Number: 2874 • 2017 ACR/ARHP Annual Meeting
Thymic Stromal Lymphopoietin (TSLP) Expression Is Associated with Lymphoproliferation and Lymphoma in Primary Sjögren’s Syndrome
Saviana Gandolfo¹, Cinzia Fabro¹, Michela Bulfoni², Sabino Russi³, Luca Quartuccio¹, Domenico Ettore Sansonno³, Carla Di Loreto², Daniela Cesselli² and Salvatore De Vita¹, ¹Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, ²Institute of Anatomic Pathology, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, ³Department of Biomedical Sciences and Human Oncology, University of Bari, Italy, Bari, Italy
Background/Purpose: Primary Sjögren’s syndrome (pSS) is an autoimmune and lymphoproliferative systemic disease with B cell hyperactivity and increased risk of non-Hodgkin lymphoma (NHL) evolution. In…
Abstract Number: 35 • 2017 ACR/ARHP Annual Meeting
B-Cell Subset Differences in Inflammatory Rheumatic Diseases
Joao Lagoas Gomes^1,2, Dario Ligeiro³, Alice Lima³, Cristina Teixeira³, Alexandre Sepriano^4,5, Sofia Ramiro⁶, Carina Lopes⁷, Tiago Costa⁸, Manuela Costa⁸, Jaime Cunha Branco^1,2 and Fernando Pimentel-Santos^1,2, ¹Rheumatology, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal, ²CEDOC, NOVA Medical School, Lisbon, Portugal, ³Centro de Sangue e Transplantação de Lisboa, Instituto Português do Sangue e Transplantação (IPST), I.P, Lisbon, Portugal, ⁴CEDOC, NOVA Medical School, Lisboa, Portugal, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁷Hospital de Egas Moniz-CHLO, Lisbon, Portugal, ⁸Rheumatology, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal
Background/Purpose: Targeting humoral immunity has been proved effective in several inflammatory rheumatic diseases (IRD). Though clinical trials have shown some efficacy of B-cell depletion in…
Abstract Number: 886 • 2017 ACR/ARHP Annual Meeting
CC-220 Decreases B-Cell Subsets and Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus (SLE) Patients and Is Associated with Skin Improvement: Pharmacodynamic Results from a Phase IIa Proof of Concept Study
Victoria P Werth¹, Richard Furie², Allison Gaudy³, Ying Ye³, Shimon Korish³, Nikolay Delev³, Douglas Hough³, Michael Weiswasser³, Suktae Choi³ and Peter Schafer³, ¹University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ²Northwell Health, Great Neck, NY, ³Celgene Corporation, Summit, NJ
Background/Purpose: CC-220 is a high affinity ligand for cereblon with immunomodulatory properties, currently in development for the treatment of Systemic Lupus Erythematosus as well as…

« Previous Page
1
…
3
4
5
6
7
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.